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Available online 20 February 2016Background: Type 2 diabetes (T2D) is a risk factor for dysregulation of glomerular ﬁltration rate (GFR) and albu-
minuria. However, whether the association is causal remains unestablished.
Research Design and Methods:We performed a Mendelian Randomization (MR) analysis in 11,502 participants
aged 40 and above, from a well-deﬁned community in Shanghai during 2011–2013, to explore the causal asso-
ciation between T2D and decreased estimated GFR (eGFR) and increased urinary albumin-to-creatinine ratio
(uACR). We genotyped 34 established T2D common variants in East Asians, and created a T2D-genetic risk
score (GRS). We deﬁned decreased eGFR as eGFR b 90 ml/min/1.73 m2 and increased uACR as uACR ≥ 30 mg/
g. We used the T2D_GRS as the instrumental variable (IV) to quantify the causal effect of T2D on decreased
eGFR and increased uACR.
Results: Each 1-standard deviation (SD, 3.90 points) increment in T2D_GRSwas associated with decreased eGFR:
odds ratio (OR) = 1.18 (95% conﬁdence interval [CI]: 1.01, 1.30). In the MR analysis, we demonstrated a causal
relationship between genetically determined T2D and decreased eGFR (OR = 1.47, 95% CI: 1.15, 1.88, P =
0.0003). When grouping the genetic loci according to their relations with either insulin secretion (IS) or insulin
resistance (IR), we found both IS_GRS and IR_GRSwere signiﬁcantly related to decreased eGFR (both P b 0.02). In
addition, T2D_GRS and IS_GRS were signiﬁcantly associated with Log-uACR (both P= 0.04).
Conclusion:Our results provide novel evidence for a causal association betweenT2D and decreased eGFR by using
MR approach in a Chinese population.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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With a rapid rise in number of type 2 diabetes (T2D) patients, dia-
betic nephropathy has become the leading cause of chronic kidney dis-
ease (CKD). In recent decades, CKD has been an important public health
problem in both developed and developing countries (Levey and
Coresh, 2012; Zhang et al., 2012). The evaluation of diabetic nephropa-
thy depends on assessment of twomarkers, albumin excretion rate and
glomerular ﬁltration rate (GFR) (Jerums et al., 2009). It is generally be-
lieved thatmicroalbuminuria is an early clinicalmanifestation of diabet-
ic nephropathy, and that decreased GFR occurs secondarily, mainly in
individuals with longstanding diabetes (Reutens, 2013). Randomized
controlled trials (RCTs) have also shown that intensive diabetes treat-
ment was associated with better renal outcomes, including lowering
risk of albuminuria and increasing estimated GFR (eGFR) (de BoerC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing a possible causal link between diabetes and renal outcomes. Howev-
er, because conventional epidemiological studies are subject to a variety
of bias such as confounding or reverse causation, and the RCTs are large-
ly limited by short-term intervention, other novel approaches are need-
ed to investigate the causal relation between T2D and renal dysfunction.
Recently, the Mendelian Randomization (MR) approach has been
widely used for assessing causality in population studies (Jansen et al.,
2014; Ding et al., 2009). Because the genetic alleles are allocated ran-
domly during gamete formation and are inherited independent of po-
tential confounding factors and represented as a life-long exposure,
using the genetic variants as the instrumental variable (IV) have be-
come a widely-used approach for causal inference (Lawlor et al., 2008).
In the present study, we performed a MR analysis to explore the
causal relation between T2D and decreased eGFR and increased uACR,
in a large community-based sample of Chinese participants. In order
to reduce the statistical errors with multi-testing, we created a T2D ge-
netic risk score (GRS) by using 34 T2D associated common variants that
were identiﬁed in East Asians and represented the comprehensive ge-
netic susceptibility of T2D, to be used as the IV (Palmer et al., 2012;
Liu and Song, 2010). In addition, we also explored the genetic variations
according to their roles in insulin secretion and insulin resistance.
2. Material and Methods
2.1. Study Participants
The present analysis was one part of an ongoing study of the Risk
Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal
(REACTION) study, which is a large, nationwide, prospective study in-
volving 259,657 community-dwelling adults, aged 40 years or older.
Details of the study rationale and proﬁle have been published elsewhere
(Ning, 2012; Bi et al., 2014). The study participants were recruited from
two nearby communities at Baoshan district in Shanghai during 2011
and 2013. A standard questionnaire was used to collect information
about lifestyle factors, disease and medical history. Anthropometric
measurements, 75-g oral glucose tolerance tests (OGTT) were per-
formed to determine the glucose metabolism status; blood and urine
samples were collected for the measurements of interests.
11,935 participants (average age 63.5 years and35.6%men)were re-
cruited, in which genotype information was available in 11,837 ones
(99.2%). Individuals with missing information on eGFR or urinary
albumin-to-creatinine ratio (uACR) (n = 95) were excluded. We fur-
ther excluded the participants who were missing more than two vari-
ants (n = 240). Thus, a total of 11,502 participants were included in
the ﬁnal analysis. The Institutional Review Board of Rui-Jin Hospital af-
ﬁliated to Shanghai Jiao Tong University School of Medicine approved
the study protocol. Written informed consent was obtained from each
participant.
2.2. Anthropometric Information and Biochemical Measurements
A standard questionnairewas used to collect the social demographic
information, the history of chronic diseases and medications, and life-
style factors such as smoking and drinking status and physical activity.
The current smoking or drinking was deﬁned as 'yes' if the subject
smoked at least one cigarette or consumed alcohol at least once a
week in the past 6month. Physical activity at leisure timewas estimated
by using the short form of the International Physical Activity Question-
naire (IPAQ) (Hagstromer et al., 2006). Trained investigators measured
body height and body weight. Bodymass index (BMI) was calculated as
weight in kilograms divided by height squared in meters (kg/m2). Sys-
tolic and diastolic blood pressures (SBP and DBP) were measured in
triplicate on the same day after at least ten-min rest by using an auto-
mated electronic device (OMRONModel HEM-752 FUZZY, Omron Com-
pany, Dalian, China), and the average value of the three measurementswas used for analysis. The SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg, or
those who were taking anti-hypertension medications were diagnosed
as hypertension.
Fasting and 2-hour post-loading plasma glucose (FPG and 2 h PG)
were measured by using hexokinase method on a clinical chemistry di-
agnostic system (C16000, Abbott Laboratories, Otawara-shi, Japan).
Serum fasting insulin was measured by using the immunoassay diag-
nostic system (I2000, Abbott Laboratories, Dallas, USA). The homeosta-
sis model assessment of insulin resistance index (HOMA-IR) was
calculated as fasting insulin (μIU/ml) × fasting glucose (mmol/l) / 22.5
(Matthews et al., 1985). The homeostasis model assessment of β cell
function or insulin secretion (HOMA-β) was calculated by using the for-
mula: HOMA-β = [20 ∗ fasting insulin (uIU/ml)] / [fasting glucose
(mmol/l) − 3.5] (Cersosimo et al., 2014). According to the 1999
World Health Organization diagnostic criteria (Alberti and Zimmet,
1998), type 2 diabetes was deﬁned as FPG ≥ 7.0 mmol/l and/or 2 h-
OGTT PG ≥ 11.1 mmol/l and/or treatment with anti-diabetic medication
and/or previously diagnosed diabetes by physicians. Fasting serum total
cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol
(HDL-cholesterol) and low-density lipoprotein cholesterol (LDL-choles-
terol) were measured by using the clinical chemistry diagnostic system
(C16000, Abbott Laboratories, Otawara-shi, Japan).
2.3. Assessment of Decreased eGFR and Increased uACR
The abbreviated Modiﬁcation of Diet in Renal Disease (MDRD) for-
mula recalibrated for Chinese was used to estimate GFR (Ma et al.,
2006). The formula was: eGFR = 186 × [serum creatinine ×
0.011]−1.154 × [age]−0.203 × [0.742 if female] × 1.233, where 1.233
was the adjusting coefﬁcient for Chinese and eGFR was expressed in
ml/min/1.73 m2. Decreased eGFR was deﬁned as eGFR b 90 ml/min/
1.73 m2 (Inker et al., 2014), with mildly decreased eGFR deﬁned as
eGFR of 60–89 ml/min/1.73 m2, and moderately to severely decreased
eGFR deﬁned as eGFR b 60 ml/min/1.73 m2.
Urinary albumin and creatinine concentrations were determined in
the ﬁrst-void sterile urine samples in the early morning by rate nephe-
lometry (Beckman Coulter, Fullerton, CA) and alkaline nitroxanthic acid
method (Beckman LX/20, Brea, CA), respectively. The increased uACR
was deﬁned as a uACR ≥ 30 mg/g, with micro-albuminuria deﬁned as
a uACR of 30–299 mg/g, and macro-albuminuria as a uACR ≥ 300 mg/g
(Reutens, 2013).
2.4. Selection of Genetic Loci, Genotyping, and Genetic Risk Score
Construction
On considering the population speciﬁcity of genetic background, the
selected variants or single nucleotide polymorphisms (SNPs)were either
discovered in Europeans and replicated in East Asians (Cho et al., 2012a;
Kato, 2013) or those identiﬁed and validated in meta-analysis including
GWASs from East Asians (Cho et al., 2012b), including: PROX1
rs213985913, BCL11 rs60357484, GCKR rs27518370, IRS1 rs226229029,
IGF2BP2 rs185793899, PPARG rs12351626, PSMD6 rs64062621, UBE2E2
rs23294959, MAEA rs1316113, CDKAL1 rs20685255, ZFAND3
rs38139068, DGKB rs15024684, GCC1/PAX4 rs127524904, JAZF1
rs28140937, SLC30A8 rs117172544, TP53INP1 rs94948283, CDKN2A/B
rs22134095, GLIS3 rs4287466, PTPRD rs8879118, CDC123/CAMK1D
rs12272998, CDC123/CAMK1D rs12286011, HHEX/IDE rs92703125,
TCF7L2 rs112998590, CENTD2 rs72722053, KCNQ1 rs2670241, KCNQ1
rs2818521, KCNJ11 rs17387083, SPRY2 rs80143021, C2CD4A/C2CD4B
rs62104190, FTO rs53779455, TCF2 (HNF1B) rs37738049, SRR
rs2312964, PEPD rs33402102 and FITM2/R3HT2DL/HNF4A rs44318326
(Supplementary Table 1). They all reached a genome-wide signiﬁcance
level (P b 5 × 10−8) and no linkage disequilibrium relationship existed
among the above loci (r2 = 0.000, except it was 0.055 between
rs10906115 and rs12779790 in CDC123/CAMK1D) according to the
data of East Asian ancestries in the International HapMap release 21.
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(Palmer et al., 2012) for each variant, applying a linear weighing of 0,
1, and 2 to genotypes containing 0, 1, or 2 risk alleles, respectively. The
weighted GRS was calculated by weighting each risk allele with the ef-
fect size (the natural log of the odds ratios [ORs]) for risk of T2D summa-
rized in the literature (Cho et al., 2012a). We excluded the participants
who were missing more than two variants (n = 240). Thus, a total of
11,502 participants were included in the ﬁnal analysis. With those who
were missing one or two variants, we assigned them the average GRS.
Using these 34 variants, we created a GRS ranging from 21.02–49.39
(weighted) and 22.00–48.42 (un-weighted). All the results in the
present study were by using the weighted GRS, and the un-weighted
GRS was used in the sensitivity analysis.
Additionally, we grouped the genetic variations according to their
associationswith insulin secretion or insulin resistance (Supplementary
Table 2). Among the 34 variants, 16 were found signiﬁcantly associated
with Log-HOMA-β and 6were associated with Log-HOMA-IR. Using the
16 insulin secretion related variants, we created a weighted IS-GRS
ranging from 6.48 to 25.60 based on weighting each allele with the ef-
fect size (β) on association with Log-HOMA-β; and using the 6 insulin
resistance related variants to create a weighted IR-GRS ranging from
3.20 to 12.00 based on weighting each allele with the effect size (β)
on association with Log-HOMA-IR.
Blood white cells were collected for DNA extractions by using
commercial blood genomic DNA extraction kit (OSR-M102-T1,
TIANGEN BIOTECH CO, LTD, Beijing, China) on an automated nucleic
acid extraction instrument (OSE-M48, TIANGEN BIOTECH CO, LTD,
Beijing, China) according to the manufacturer's standard protocol.
Speciﬁc assays were designed using the MassARRAY Assay Design
software package (v3.1) (https://www.agenacx.com/Home). Mass
determination was carried out with theMALDI-TOF mass spectrometer
and data acquisition was used MassARRAY Type 4.0 software
(SEQUENOM, CapitalBio Corporation, Beijing, China). The minimum
call rate was 98.7%. The concordance rate is more than 99% based on
100 duplicates genotyping. Most of the SNPs were in Hardy–Weinberg
equilibrium (HWE).
2.5. Statistical Analysis
SAS version 9.3 (SAS Institute, Cary, NC) was used for database
management and statistical analysis. Serum TG, HOMA-IR and
HOMA-β were normalized by logarithmic transformation because
of skewed distributions. Continuous variables were given as age-,
sex- and BMI-adjusted means ± standard error [SE]. Categorical var-
iables were shown in proportions. Linear regression analysis and
Cochran–Armitage trend chi-square test were used to test for trends
across the T2D_GRS quartiles for continuous variables and categori-
cal variables. Multivariable-adjusted linear regression models were
ﬁtted to evaluate the association of T2D-, IR- and IS-GRS with Log-
eGFR and Log-uACR, respectively. Multivariable logistic regression
models were used to assess the associations between the GRSs and
decreased eGFR and increased uACR. The adjustment included age
(years), sex, BMI (kg/m2), current smoking (yes or no), current
drinking (yes or no), physical activity (mild, moderate or vigorous),
hypertension (yes or no), total cholesterol (mmol/l), HDL-
cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides
(mmol/l). Multinomial logistic regression models were ﬁtted to as-
sess the associations of T2D-GRS with mildly and moderately to se-
verely decreased eGFR, as well as micro- and macro-albuminuria.
Statistical signiﬁcance was set to a two-sided P value of less than
0.05.
In the MR analysis, we used the IV estimators to measure the
strength of the causal relationship between T2D and decreased eGFR
and increased uACR. The IV estimate of causal OR was derived by
using the Wald-type estimator (Fall et al., 2013) and then
exponentiating to express as an OR. The computational formula wasORIV = exp (Ln (OR GRS − outcome) / Ln (OR GRS − T2D)), in which Ln
(OR GRS − outcome) was βGRS-outcome and Ln (OR GRS − T2D) was βGRS-T2D.
The SE for the IV estimators was estimated using the delta method.
SEIV ¼ abs βIVð Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SEGRST2D
βGRST2D
 2
þ SEGRSoutcome
βGRSoutcome
 2s
Based on these estimates, we appeal to standard-normal asymp-
totics, with the resultingWald test statistic and 95% conﬁdence intervals
(CIs) given as
ZIV ¼ βIVSEIV ORIV ¼ exp βIVð Þ 95% CIIV ¼ exp βIV  1:96 SEIVð Þ
The P-value for the H0: βIV=0 was derived from the standard
normal distribution. For the ORs associated with dichotomous traits
(decreased eGFR or increased uACR), the 95% CI estimates were back-
transformed through the exponentiation.
The IV estimates were adjusted for age (years), sex, BMI (kg/m2),
current smoking (yes or no), current drinking (yes or no), physical ac-
tivity (mild, moderate or vigorous), hypertension (yes or no), total cho-
lesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l)
and triglycerides (mmol/l).
3. Results
3.1. Characteristics of Study Participants
The characteristics of individual variants included in the T2D_GRS
and their associations with T2D were shown in Supplementary Table 1.
Mean value of the weighted T2D_GRS was 34.53 with a standard devia-
tion (SD) of 3.90 (Supplementary Figure 1). Sociodemographic and clin-
ical characteristics of participants according to quartiles of weighted
T2D_GRS were displayed in Table 1. Among the 11,502 participants,
4101 (35.7%) were men and 2869 (24.9%) were T2D patients. The aver-
age age was 63.3 years (SD, 13.5). The levels of serum creatinine and
uACR were increasing across T2D_GRS quartiles, while the eGFR levels
were decreasing. The prevalence of decreased eGFR was increasing
across the T2D_GRS quartiles (P for trend = 0.02).
3.2. Associations of T2D-GRS with Decreased eGFR and Increased uACR
As shown in Table 2, per SD (3.90 points) increase in T2D_GRS was
associated with 12% increased risk of decreased eGFR after adjustment
for age, sex and BMI (95% CI: 1.04, 1.20, P=0.001). Further adjustment
for current smoking and current drinking, physical activity, hyperten-
sion and serum lipids did not appreciably change the results (OR =
1.12, 95% CI: 1.04, 1.20, P = 0.002). The categorical analysis showed
similar results. Compared with the lowest quartile of T2D_GRS, the sec-
ond, third and highest quartiles were associated with 15%, 19% and 34%
increased risk of decreased eGFR, respectively, after adjustment for age,
sex, BMI and other covariates (P for trend = 0.005). We did not ﬁnd
positive results between T2D_GRS and increased uACR after adjusted
for age, sex, BMI and other covariates. The associations of each SNP
with decreased eGFR and increased uACRwere shown in Supplementa-
ry Table 3.
3.3. Associations of T2D with Decreased eGFR and Increased uACR: The MR
Analysis
Fig. 1 Panel A shows the comparison of the observed and the IV caus-
al estimated association of T2D with decreased eGFR and increased
uACR. T2D was signiﬁcantly associated with decreased eGFR OR =
1.18 (95% CI: 1.01, 1.38), after adjustment for age (years), sex, BMI
(kg/m2), current smoking (yes or no), current drinking (yes or no),
physical activity (mild, moderate or vigorous), hypertension (yes or
Table 1
Characteristics of the participants according to quartiles of weighted T2D_GRS.
n T2D_GRS P for trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
2875 2875 2877 2875 /
Age, years 63.2 ± 0.3 63.4 ± 0.3 63.3 ± 0.3 63.2 ± 0.3 0.91
Male, n, % 990 (34.3) 981 (34.1) 1056 (36.7) 1074 (37.4) 0.005
Current smoker, n (%) 395 (14.6) 391 (14.5) 411 (15.1) 438 (16.1) 0.10
Current drinker, n (%) 240 (8.9) 245 (9.1) 264 (9.8) 280 (10.3) 0.04
BMI, kg/m2 25.44 ± 0.07 24.36 ± 0.07 25.20 ± 0.07 25.11 ± 0.07 0.0004
FPG, mmol/l 5.78 ± 0.03 5.97 ± 0.03 6.09 ± 0.03 6.20 ± 0.03 b0.0001
2 h PG, mmol/l 8.32 ± 0.07 8.82 ± 0.07 9.06 ± 0.07 9.40 ± 0.07 b0.0001
Log-HOMA-IR 0.47 ± 0.01 0.49 ± 0.01 0.50 ± 0.01 0.50 ± 0.01 0.02
Log-HOMA-β, % 4.13 ± 0.01 4.06 ± 0.01 4.02 ± 0.01 3.97 ± 0.01 b0.0001
Log-TG, mmol/l 0.29 ± 0.009 0.28 ± 0.009 0.28 ± 0.009 0.29 ± 0.009 0.98
Total cholesterol, mmol/l 4.93 ± 0.02 4.94 ± 0.02 4.95 ± 0.02 4.96 ± 0.02 0.44
SBP, mm Hg 136.3 ± 0.4 136.9 ± 0.4 137.2 ± 0.4 137.2 ± 0.4 0.06
DBP, mm Hg 77.5 ± 0.2 77.2 ± 0.2 77.4 ± 0.2 76.9 ± 0.2 0.28
Hypertension, n (%) 1680 (58.5) 1644 (57.2) 1655 (57.5) 1648 (57.4) 0.47
Diabetes, n (%) 527 (18.3) 689 (24.0) 756 (26.3) 897 (31.2) b0.0001
Log-Creatinine, mg/dl 4.17 ± 0.003 4.18 ± 0.003 4.18 ± 0.003 4.19 ± 0.003 0.04
Log-eGFR, ml/min/1.73 m2 4.77 ± 0.004 4.76 ± 0.004 4.75 ± 0.004 4.75 ± 0.004 0.04
Log-uACR, mg/g 2.16 ± 0.02 2.19 ± 0.02 2.21 ± 0.02 2.23 ± 0.02 0.02
Decreased eGFR, n (%) 231 (8.0) 257 (8.9) 264 (9.2) 283 (9.8) 0.02
Increased uACR, n (%) 306 (10.6) 318 (11.1) 331 (11.5) 340 (11.8) 0.13
Data are age-, sex- and BMI-adjustedmeans± standard errors (SE) for continuous variables or proportions for categorical variables. P for trendwas calculated from the age-, sex- and BMI-
adjusted linear regressions and Cochran–Armitage trend chi-square tests, respectively. T2D-GRS: type 2 diabetes genetic risk score; BMI: bodymass index; FPG: fasting plasma glucose; 2 h
PG: 2 h post-loading plasma glucose; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β cell function; TG: triglyceride; uACR:
urinary albumin-to-creatinine ratio; eGFR: estimated glomerularﬁltration rate. Decreased eGFRwas deﬁned as eGFR b 90ml/min/1.73m2; increaseduACRwasdeﬁned as uACR ≥ 30mg/g.
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cholesterol (mmol/l) and triglycerides (mmol/l). In the MR analysis,
we found a signiﬁcant causal relationship between genetically deter-
mined T2D and decreased eGFR, with the OR of 1.47 (95% CI, 1.15,
1.88, P= 0.0003).
Panel B shows the comparison of the observed and the IV causal es-
timated association of T2D with increased uACR. The observational
analysis showed that T2D was signiﬁcantly associated with increased
uACR, OR = 2.15 (95% CI: 1.88, 2.45) after same adjustments as Panel
A. While the MR analysis did not show a signiﬁcant causal association,Table 2
The associations of weighted T2D_GRS with decreased eGFR and increased uACR.
Model 1 Model 2
OR (95% CI) P value OR (95% CI) P value
Decreased eGFR, eGFR b 90 ml/min/1.73 m2
Continuous variable of T2D_GRS, per SD, 3.90
1.12 (1.04, 1.20) 0.001 1.12 (1.04, 1.20) 0.002
Categorical variable of T2D_GRS
Q1 1.00 0.004 1.00 0.005
Q2 1.16 (0.95, 1.41) 1.15 (0.94, 1.41)
Q3 1.19 (0.98, 1.44) 1.19 (0.97, 1.45)
Q4 1.33 (1.10, 1.61) 1.34 (1.10, 1.12)
Increased uACR, uACR ≥ 30 mg/g
Continuous variable of T2D_GRS, per SD, 3.90
1.05 (0.99, 1.12) 0.09 1.05 (0.98, 1.11) 0.16
Categorical variable of T2D_GRS
Q1 1.00 0.04 1.00 0.09
Q2 1.06 (0.89, 1.25) 0.99 (0.83, 1.19)
Q3 1.12 (0.95, 1.33) 1.10 (0.92, 1.31)
Q4 1.17 (0.99, 1.38) 1.13 (0.95, 1.35)
Data are odds ratios (ORs) and 95% conﬁdence intervals (CIs). P values were calculated
from the multivariable-adjusted logistic regression models. Model 1, is adjusted for age,
sex and BMI; Model 2, further adjusted for current smoking (yes or no), current drinking
(yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total
cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycer-
ides (mmol/l). T2D_GRS: type 2 diabetes genetic risks score; eGFR: estimated glomerular
ﬁltration rate; uACR: urinary albumin-to-creatinine ratio; SD: standard deviation; Q1:
quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4.with the causal OR of genetically determined T2D for increased uACR,
OR = 1.17 (95% CI: 0.94, 1.45).
We also showed the IV estimated results for associations of each in-
dividual SNPwith decreased eGFR and increased uACR in Supplementa-
ry Table 4. The results were similar with the association study in
Supplementary Table 3.
3.4. Association of Function-speciﬁc GRS with Decreased eGFR and In-
creased uACR
Fig. 2 shows that per SD (2.52 points) increase in IS_GRS was signif-
icantly associated with decreased eGFR, OR = 1.11 (95% CI: 1.04, 1.19,
P = 0.004) and increased uACR, OR = 1.07 (95% CI: 1.002, 1.13, P =
0.04), after adjustment of age (years), sex, BMI (kg/m2), current
smoking (yes or no), current drinking (yes or no), physical activity
(mild,moderate or vigorous), hypertension (yes or no), total cholesterol
(mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and tri-
glycerides (mmol/l). Similarly, we found a signiﬁcant association be-
tween IR_GRS with decreased eGFR (OR = 1.09, 95% CI: 1.01, 1.17,
P = 0.02); while no signiﬁcant association was found with increased
uACR (P = 0.95). The IS_GRS was associated with Log-eGFR and Log-
uACR (both P= 0.04). However, the IR_GRS was only associated with
Log-eGFR (P= 0.007), but not Log-uACR (P= 0.23, Fig. 3).
When classiﬁed decreased eGFR asmildly decreased andmoderately
to severely decreased eGFR, we found that the T2D_GRS, IS_GRS and
IR_GRS were signiﬁcantly related to mildly decreased eGFR (all
P ≤ 0.03), but not moderately to severely decreased eGFR (Supplemen-
tary Table 5). When classiﬁed increased uACR into micro- and macro-
albuminuria, we found that both T2D_GRS and IS_GRSwas signiﬁcantly
associated with macro-albuminuria (P ≤ 0.02), but not micro-
albuminuria. We did not ﬁnd any positive relationship of IR_GRS with
micro-albuminuria or with macro-albuminuria (Supplementary
Table 5).
3.5. Sensitivity Analysis
In agreementwith the conjecture, we observed a consistent and sig-
niﬁcant association between genetically determined T2D and decreased
Fig. 1. Observed versus the IV estimated association of T2D with decreased eGFR and increased uACR. In the MR framework, T2D_GRS-T2D association is assumed to be independent of
confounders. All the analyses were adjusted for age (years), sex, BMI (kg/m2), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous),
hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l).
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weighted T2D-GRS as the IV, as shown in Fig. 4. When using the un-
weighted T2D_GRS as the IV, we found that genetically determined
T2D was causally associated with increased uACR (OR = 1.24, 95% CI:
1.02, 1.53, P = 0.02), though we did not ﬁnd a causal association
using the weighted T2D_GRS as the IV. We excluded the 9 SNPs thatare not in HWE (Supplementary Table 1, rs1801282, rs831571,
rs6467136, rs864745, rs13266634, rs89654, rs17584499, rs111187
and rs1552224) and created a new T2D_GRS/25 SNP with a mean of
26.10 (SD, 3.52). In the MR analysis, after adjustment of age, sex, BMI,
current smoking, current drinking, physical activity, hypertension,
total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides,
Fig. 2.Associations of IS_GRS and IR_GRSwith decreased eGFR and increased uACR IS_GRS: insulin secretion associated genetic risk score; IR_GRS: insulin resistance associated genetic risk
score. Data were presented as odds ratios (ORs) and 95% conﬁdence intervals (CIs). P values were calculated from a multivariable logistic regression models after adjustment for age
(years), sex, BMI (kg/m2), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/
l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l).
167M. Xu et al. / EBioMedicine 6 (2016) 162–170the IV estimate for causal relationship between T2Dand decreased eGFR
was, OR = 1.42 (95% CI: 1.13–1.79, P = 0.0005) (Fig. 4 and
Supplementary 2 Panel A).
The T2D_GRSwas found to relate to BMI and SBP, in addition to FPG,
OGTT-2 h PG, HOMA-IR andHOMA-β (Supplemental Table 6). To lessen
the potential inﬂuence of pleiotropic effects of the IV, we performedFig. 3. The associations of different GRSs with log-eGFR and log-uACR. Data are presented as r
multivariable linear regression models, after adjustment for age (years), sex, BMI (kg/m2), cur
or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l),
risk score; IR_GRS: insulin resistance associated genetic risk score; IS_GRS: insulin secretion
albumin-to-creatinine ratio.sensitivity analysis by excluding the 16 SNPs linking to BMI, SBP, DBP,
TC and TG (Supplemental Table 7, rs5215, rs4402960, rs1111875,
rs243021, rs231362, rs10906115, rs3786897, rs9356744, rs17817449,
rs6017317, rs17584499, rs2191349, rs1552224, rs7612463,
rs13266634 and rs780094), the T2D_GRS composing the SNPs only as-
sociatedwith T2Dwas associatedwith decreased eGFR (Supplementaryegression coefﬁcient (β) and 95% conﬁdence interval (CI). P values were calculated from
rent smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate
LDL-cholesterol (mmol/l) and triglycerides (mmol/l). T2D_GRS: type 2 diabetes genetic
associated genetic risks score; eGFR: estimated glomerular ﬁltration rate; uACR: urinary
Fig. 4. Sensitivity analysis of the associations of genetically determined T2D with decreased eGFR and increased uACR. Data were presented as odds ratios (ORs) and 95% conﬁdence
intervals (CIs). P values were adjusted for age (years), sex, BMI (kg/m2), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous),
hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). T2D_GRS: type 2 diabetes genetic risk score; SD:
standard deviation. T2D_GRS/25 SNP was calculated from the SNPs after excluding those were out of Hardy–Weinberg equilibrium (rs1801282, rs831571, rs6467136, rs864745,
rs13266634, rs89654, rs17584499, rs111187 and rs1552224). T2D_GRS/18 SNP was calculated using the SNPs after excluding those may have potential pleiotropic effects (rs5215,
rs4402960, rs1111875, rs243021, rs231362, rs10906115, rs3786897, rs9356744, rs17817449, rs6017317, rs17584499, rs2191349, rs1552224, rs7612463, rs13266634 and rs780094).
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tionship of T2D and decreased eGFR was: OR = 1.38 (95% CI: 1.02,
1.85, P= 0.02) (Fig. 4 and Supplementary 3).4. Conclusions
In the present investigation including 11,502 community dwelling
Chinese adults, we found that T2D_GRS composing of 34 T2D common
variants discovered in East Asians was signiﬁcantly associated with de-
creased eGFR. To the best of our knowledge, the results for the ﬁrst time
provided novel evidence for a causal relationship between genetically
determined T2D and decreased kidney function by using MR.
The MR analysis is a recent improvement in genetic epidemiology
(Jansen et al., 2014; Ding et al., 2009; Didelez and Sheehan, 2007). The
independent distribution of alleles/genotypes means that the associa-
tion of a disease with a genetic variation would not be affected by
confounders (Qi, 2009). Moreover, because the random assignment of
alleles/genotype transferred from parent to offspring occurs at the
time of gamete formation, the association between a genetic variation
and a disease is free of reverse causation. Besides, MR study is linked
to a natural RCT according to themethodology and has particular supe-
riority in assessing the effects of long-term or lifetime exposures (Qi,
2009). Previous MR studies have provided signiﬁcant evidence to sup-
port causal links between biomarkers, traits and cardiovascular diseases
(Davey Smith and Hemani, 2014; Jensen et al., 2013; Rasmussen-Torvik
et al., 2011). Our results were consistent with the latest twoMR studies
which have provided a causal relationship between diabetes and coro-
nary artery disease using diabetes GRS as the IV (Ross et al., 2015;
Ahmad et al., 2015). Our study, for the ﬁrst time, provided potentialcausal evidence between genetically determined T2D and mild renal
sufﬁciency assessed by decreased eGFR using the MR approach.
Earlier stages of renal insufﬁciency can be detected through serum
creatinine and eGFR (K/DOQI, 2002). Individuals with T2D and reduced
eGFR have been shown to be at high risk of cardiovascular events, inde-
pendent of albuminuria andmetabolic control (So et al., 2006). Very re-
cently, one study reported that serum urate was causally associated
with improved renal function using GRS of uric acid transporters as
the IV, implying the mechanism of the potential renal function protec-
tion mediated by xanthine oxidase inhibitors (Hughes et al., 2014). In
the present investigation, we found that T2D_GRS was signiﬁcantly
associated with decreased eGFR, especially mildly decreased eGFR.
Intriguingly, consistent results were obtained when restricting the MR
analysis to genetic variations related to decreased insulin secretion
and insulin resistance, suggesting that dysfunction in both insulin secre-
tion and insulin sensitivity may causally affect renal insufﬁciency.
Though further replications in other populations are needed, our ﬁnd-
ings suggest that that long-term treatment with T2D may be beneﬁcial
for prevention of diabetic renal impairment.
Measurement of urinary albumin excretion can identify patientswith
kidney damage (K/DOQI, 2002). Microalbuminuria is now considered as
a marker for early diabetic nephropathy (Viberti et al., 1982) and an in-
dependent predictor for cardiovascular disease and mortality (Dinneen
and Gerstein, 1997). Macroalbuminuria is the common manifestation
in progressive renal disease, and is viewed as a measurement of the se-
verity and determinant for diabetic renal disease progression (K/DOQI,
2002). In our present study, we only found a signiﬁcant association
between T2D_GRS and macroalbuminuria, but not microalbuminuria.
Despite this, we also found that T2D_GRS was linearly related to Log-
uACR.Whenusing the un-weighted T2D_GRS, IS_GRS andGRS excluding
169M. Xu et al. / EBioMedicine 6 (2016) 162–170those SNPs not inHWE (T2D_GRS/25 SNP) as the IVs,we found a causal as-
sociation between genetically determined T2D and increased uACR in
the sensitivity analysis. Thus, our data also suggest potential causal rela-
tion between genetically determined T2D and albuminuria. Additional
larger sample size MR studies or systemically functional investigations
are needed to conﬁrm this conjecture.
Several assumptions should bewellmet in performing aMR analysis
(Qi, 2009). Firstly, the IV must not be correlated with confounders. In
our study, the T2D_GRS was found to be associated with diabetes and
diabetes-associated traits, but not with smoking, or drinking habits,
physical activity, lipids or blood pressure, which are major risk factors
for the renal disease. Nevertheless, the T2D_GRS was found to be asso-
ciated with BMI and sex. To lessen the potential inﬂuence of pleiotropic
effects of the IV, we examined the association of each SNP with other
traditional factors related to decreased eGFR and increased uACR, such
as BMI, SBP, DBP, TG and TG and performed sensitivity analysis by ex-
cluding those SNPs that associated with these metabolic traits. The IV
estimated causal relationship remained signiﬁcant. Secondly, the IV
was strongly associated with exposure of interest. All variants used in
this study have previously been shown to be strong associated with
T2D in large meta-analysis of GWAS and could mostly be replicated in
our present study. Thirdly, the IV related to outcome only through the
exposure of interest. There should be nodirect effect of genotype on dis-
ease or any othermediated effectors other than through the exposure of
interest. Though this assumption is considered largely untestable, fur-
ther adjustments of other potential confounders/mediators did change
the results slightly in our analysis.We hypothesized that the association
between genetically determined T2D with risk of decreased GFR is due
to a direct consequence of being diabetes. We could not exclude the
possibility that the associations of the genetic variants with T2D and
with decreased eGFR are through completely different mechanisms.
Pathway analysis in large meta-GWAS study or animal studies is war-
ranted for verifying this assumption.
The strength of our study included the relative large sample size,
well-deﬁned community setting and the highly homogeneous popula-
tion, theMR study design and a created T2D_GRS representing the com-
bined effect of the established common genetic variants of T2D used as
the IV. Several limitations should be acknowledged. Firstly, we used
serum creatinine estimated GFR as marker of renal function, which
thought to be usually accurate when GFR is below 60 ml/min and less
accurate at normal or high GFR (Jerums et al., 2009). The serum creati-
nine estimated GFR is widely used in the epidemiological studies due to
good availability. Nevertheless, new methods such as the use of
cystatin-C-based equations for estimating GFR would be considered in
the future analysis. Secondly, the T2D_GRS only consisted of the validat-
ed common variants, which was considered to represent limited diabe-
tes heritability so far. We were unable to assess the potential
contribution of rare variants. Thirdly, though this study provided in-
sights into the potentially causal effect of lifetime exposure of hypergly-
cemia, further investigations are needed to illustrate the precise
mechanisms. Fourthly, because of the cross-sectional design, our ﬁnd-
ingsmay suggest the association is causal, further studies in prospective
cohorts are needed to verify our ﬁndings. Finally, we created the
T2D_GRS by using the common variants robustly associated with T2D
in East Asians; it needs to be cautious to generalize the ﬁndings to
other ethnicities or ethnic groups.
In conclusion, we found that a higher T2D_GRS was associated with
higher risk of decreased eGFR. This analysis provides evidence for the bi-
ologically plausible causal relationship between genetically determined
T2D and renal insufﬁcient. Additional studies are needed to validate our
ﬁndings and elucidate the mechanisms behind these ﬁndings.
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